Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Clin Microbiol Infect ; 20(10): O721-9, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24330047

RESUMEN

In patients with community-onset acute pyelonephritis (CO-APN), assessing the risk factors for poor clinical response after 72 h of antibiotic treatment (early clinical failure) is important. The objectives of this study were to define those risk factors, and to assess whether early clinical failure influences mortality and treatment outcomes. We prospectively collected the clinical and microbiological data of women with CO-APN in South Korea from March 2010 to February 2012. The numbers of cases in the early clinical success and early clinical failure groups were 840 (79.1%) and 222 (20.9%), respectively. Final clinical failure and mortality were higher in the early clinical failure group than in the early clinical success group (14.9% vs 2.3%, p <0.001; 6.8% vs 0.1%, p 0.001, respectively). In a multiple logistic regression model, the risk factors for early clinical failure among the total 1062 patients were diabetes mellitus (OR 1.5; 95% CI 1.1-2.1), chronic liver diseases (OR 3.3; 95% CI 1.6-6.7), malignancy (OR 2.2; 95% CI 1.1-4.4), Pitt score ≥2 (OR 2.5; 95% CI 1.6-3.8), presence of azotaemia (OR 1.8; 95% CI 1.2-2.7), white blood cell count ≥20 000/mm(3) (OR 2.5; 95% CI 1.6-4.0), serum C-reactive protein level ≥20 mg/dL (OR 1.7; 95% CI 1.2-2.4), and history of antibiotic usage within the previous year (OR 1.5; 95% CI 1.1-2.2). Analysing the subgroup of 743 patients with CO-APN due to Enterobacteriaceae, fluoroquinolone resistance of the uropathogen was another factor associated with early clinical failure (OR 1.7; 95% CI 1.1-2.5). Simple variables of underlying diseases, previous antibiotic usage and initial laboratory test outcomes can be used to decide on the direction of treatment in CO-APN.


Asunto(s)
Antibacterianos/administración & dosificación , Pielonefritis/tratamiento farmacológico , Pielonefritis/mortalidad , Adulto , Anciano , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/mortalidad , Femenino , Humanos , Persona de Mediana Edad , Estudios Prospectivos , Análisis de Regresión , República de Corea/epidemiología , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores de Tiempo , Insuficiencia del Tratamiento
2.
Epidemiol Infect ; 140(1): 137-45, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21554783

RESUMEN

Carbapenem-resistant Acinetobacter baumannii (CRAB) are an increasing infectious threat in hospitals. We investigated the clinical epidemiology of CRAB infections vs. colonization in patients, and examined the mechanisms of resistance associated with elevated minimum inhibitory concentrations (MICs) for carbapenems. From January to June 2009, 75 CRAB strains were collected. CRAB infection was significantly associated with malignancy and a high APACHE II score. The most dominant resistance mechanism was ISAba1 preceding OXA-51, producing strains with overexpression of efflux pump. Strains carrying blaOXA-23-like enzymes had higher carbapenem MICs than those carrying blaOXA-51-like enzymes; however, the presence of multiple mechanisms did not result in increased resistance to carbapenems. There was no difference in the resistance mechanisms in strains from infected and colonized patients. The majority of strains were genetically diverse by DNA macrorestriction although there was evidence of clonal spread of four clusters of strains in patients.


Asunto(s)
Infecciones por Acinetobacter/microbiología , Acinetobacter baumannii/fisiología , Antibacterianos/farmacología , Carbapenémicos/farmacología , Infección Hospitalaria/microbiología , Infecciones por Acinetobacter/epidemiología , Acinetobacter baumannii/efectos de los fármacos , Acinetobacter baumannii/genética , Acinetobacter baumannii/aislamiento & purificación , Adulto , Anciano , Anciano de 80 o más Años , Distribución de Chi-Cuadrado , Análisis por Conglomerados , Infección Hospitalaria/epidemiología , Electroforesis en Gel de Campo Pulsado , Femenino , Humanos , Imipenem/farmacología , Masculino , Meropenem , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Epidemiología Molecular , República de Corea/epidemiología , Factores de Riesgo , Estadísticas no Paramétricas , Tienamicinas/farmacología , Resistencia betalactámica
3.
Transpl Infect Dis ; 10(5): 316-24, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18507752

RESUMEN

BACKGROUND: Infectious complications following living-donor liver transplantation (LDLT) remain a major cause of morbidity and mortality. We analyzed the frequency and type of infectious complications according to the post-transplantation period, and their risk factors with regard to morbidity and mortality. METHODS: We retrospectively analyzed 208 subjects who had undergone LDLT during a 9-year period. RESULTS: The rate of infection was 1.69 per patient during the study period. The predominant infections were intra-abdominal infections (37.6%), primary bacteremia (17.4%), and pneumonia (14.5%). Within the first post-transplant month, 140 (39.9%) infections were detected, and catheter-related coagulase-negative staphylococci (44) were the most common infectious agents. During the 2-6-month post-transplant period, 109 infectious episodes occurred (31.1%), and Enterococcus sp. (n=16) related to biliary infection was the most frequent isolate. After the sixth month, 96 infectious episodes (29%) occurred, and biliary tract-related Escherichia coli (n=19) was the major causative organism. The overall mortality was 24.5% (51/208); 1-year survival rate was 88% (196/208). Post-transplant infection-related mortality was 52.9% (27/51). Biliary tract complications, such as biliary stenosis or leakage, significantly increased the mortality (P=0.01); however, reoperation (retransplantation or resurgery for biliary tract obstruction/leakage or to control bleeding) significantly reduced the mortality (P=0.01). CONCLUSIONS: Our data showed that early catheter removal would mainly aid in reducing infectious complications in the 1-month post-transplantation period. Aggressive management, including reoperation, would lower the mortality in the LDLT recipients.


Asunto(s)
Infecciones/epidemiología , Trasplante de Hígado/efectos adversos , Donadores Vivos , Complicaciones Posoperatorias/epidemiología , Acondicionamiento Pretrasplante/efectos adversos , Bacteriemia/epidemiología , Bacteriemia/etiología , Bacteriemia/mortalidad , Enfermedades de las Vías Biliares/epidemiología , Enfermedades de las Vías Biliares/etiología , Enfermedades de las Vías Biliares/mortalidad , Femenino , Humanos , Infecciones/etiología , Infecciones/mortalidad , Corea (Geográfico)/epidemiología , Masculino , Persona de Mediana Edad , Peritonitis/epidemiología , Peritonitis/etiología , Peritonitis/mortalidad , Neumonía/epidemiología , Neumonía/etiología , Neumonía/mortalidad , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/mortalidad , Reoperación , Estudios Retrospectivos , Factores de Riesgo , Tasa de Supervivencia , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA